Neil Gunn
Patrimonio netto: 538 382 $ in data 31/05/2026
Patrimonio netto: 538 382 $ in data 31/05/2026
Dr. Neil Gunn is an Independent Director at NeoGenomics, Inc., an Independent Director at Rarecells, Inc. and an Independent Director at Alveo Technologies, Inc. He is on the Board of Directors at NeoGenomics, Inc., Rarecells, Inc., Alveo Technologies, Inc. and Rarecells Diagnostics SAS. Dr. Gunn was previously employed as a Chief Executive Officer & Director by IDbyDNA, Inc., a Non-Executive Director by Genetic Signatures Ltd., a President by Roche Sequencing Solutions, Inc., a Vice President-Commercial Operations by CaridianBCT, Inc., a Vice President-Commercial Operations by Novartis Vaccines & Diagnostics SL, and a Head-Global Business by Roche Molecular Systems, Inc. He received his undergraduate degree from Nottingham Trent University, a graduate degree from the University of Portsmouth and a doctorate degree from the University of Portsmouth.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
NEOGENOMICS, INC. 0,04% | 01/06/2026 | 51.177 ( 0,04% ) | 538 382 $ | 31/05/2026 |
| 08/05/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| NEOGENOMICS, INC. | Direttore/Membro del Consiglio | 26/06/2023 |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices | Direttore/Membro del Consiglio | 13/05/2021 |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Develops and commercializes technology to isolate circulating cancer cells for early cancer diagnosis and medical research | Direttore/Membro del Consiglio | 06/09/2022 |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Develops and commercializes ISET technology to isolate circulating cancer cells for early cancer diagnosis & medical research | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| GENETIC SIGNATURES LIMITED | Amministratore Delegato | 30/09/2024 |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology Develops technologies that will enable nucleic acid based identification testing services | Amministratore Delegato | 01/01/2022 |
CaridianBCT, Inc.
CaridianBCT, Inc. Medical/Nursing ServicesHealth Services Designs, develops and supplies blood components | Corporate Officer/Principal | - |
Novartis Vaccines & Diagnostics SL | Corporate Officer/Principal | - |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
NeoGenomics, Inc.
NeoGenomics, Inc. Medical/Nursing ServicesHealth Services Provides genetic and molecular testing services | Health Services |
Nottingham Trent University
Nottingham Trent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CaridianBCT, Inc.
CaridianBCT, Inc. Medical/Nursing ServicesHealth Services Designs, develops and supplies blood components | Health Services |
Genetic Signatures Ltd.
Genetic Signatures Ltd. Miscellaneous Commercial ServicesCommercial Services Develops and commercializes diagnostic kits | Commercial Services |
University of Portsmouth
University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Molecular Systems, Inc.
Roche Molecular Systems, Inc. Medical/Nursing ServicesHealth Services Develops & produces molecular-based diagnostic tests & automated testing platforms | Health Services |
Novartis Vaccines & Diagnostics SL | |
Rarecells USA, Inc.
Rarecells USA, Inc. Packaged SoftwareTechnology Services Develops and commercializes technology to isolate circulating cancer cells for early cancer diagnosis and medical research | Technology Services |
IDbyDNA, Inc.
IDbyDNA, Inc. BiotechnologyHealth Technology Develops technologies that will enable nucleic acid based identification testing services | Health Technology |
Alveo Technologies, Inc.
Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices | Health Technology |
Roche Sequencing Solutions, Inc.
Roche Sequencing Solutions, Inc. Medical/Nursing ServicesHealth Services Provides diagnostics and treatments services | Health Services |
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Develops and commercializes ISET technology to isolate circulating cancer cells for early cancer diagnosis & medical research | Technology Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale